NFE2L2 and small cell lung carcinoma: Therefore, IHC-labeling of lung tumors with markers specific for NRF2, along with NE, SCC and LUAD markers is recommended before and after treatment to monitor for transformation to more aggressive tumors (i.e. SCLC and LUSC).